JAMA:omega-3 fatty acids had no significant clinical benefits for high-risk cardiovascular patients who were receiving statin therapy

Omega-3 fatty acids (omega-3 CA), such as pyrethroids (EPA) and DHA, have long been considered beneficial for cardiovascular disease risk, but they have not been confirmed in large-scale clinical trials, and researchers recently examined the effects of a preparation containing EPA and DHA on atherosclerotic lipid abnormalities and lipids and inflammatory markers in patients at high cardiovascular risk.
The double-blind, randomized, multicenter trial was conducted at 675 medical centers in 22 countries in North America, Europe, South America, Asia, Australia, New Zealand and South Africa, and the researchers looked at the high cardiovascular risk, high triglycerideemia and HDL cholesterol (HD) L-C) low-level population effects, participants received statin therapy, a total of 13,078 patients, randomly received 4g/d of omega-3 CA (n=6539) or corn oil (control group, n=6539).
indicators of efficacy in this study include cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary artery hemodynamic reconstruction, or unstable angina that requires hospitalization.
-term analysis, a total of 1,384 patients had major endpoint events, and the study was discontinued early.
results show that omega-3-CA is less likely to benefit clinically than corn oil.
participants had an average age of 62.5 years, 35% female and 70% diabetic, with an average LDL cholesterol level of 75.0 mg/dL and an average triglyceride level of 2 40 mg/dL, average HDL-C level 36mg/dL, average high sensitivity C reactive protein level 2.1 mg/L, 12633 patients (96.6%) completed the trial.
785 (12.0%) of patients treated with omega-3 CA had a major endpoint event, compared with 795 patients in the corn oil group (12.2% with a risk ratio of 0.99).
the omega-3 CA group had a higher rate of gastrointestinal adverse events (24.7%) than patients treated with corn oil (14.7%). the
study found that for patients at high risk of cardiovascular disease who were being treated with statins, adding omega-3 fatty acids to conventional therapy had no significant effect on the overall outcomes of major cardiovascular adverse events, and the study did not support the use of omega-3 fatty acids to reduce the risk of major cardiovascular adverse events in high-risk patients.